FULC Stock Price, Fulcrum Therapeutics Inc Quote, Chart

Market Summary

USD7.29-0.15

Market Closed

-2.02%

FULC Stock Price

View Fullscreen

FULC RSI Chart

FULC Valuation

Market Cap

460.8M

Price/Earnings (Trailing)

-4.73

Price/Sales (Trailing)

164.28

Price/Free Cashflow

-5.04

FULC Price/Sales (Trailing)

FULC Profitability

Return on Equity

-41.39%

Return on Assets

-37.77%

Free Cashflow Yield

-19.85%

FULC Fundamentals

FULC Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

27.15%

Rev. Growth (Qtr)

14.76%

FULC Earnings

Earnings (TTM)

-97.3M

Earnings Growth (Yr)

5.28%

Earnings Growth (Qtr)

-3.08%

Breaking Down FULC Revenue

Last 7 days

0.4%

Last 30 days

-23.1%

Last 90 days

11.0%

Trailing 12 Months

180.8%

How does FULC drawdown profile look like?

FULC Financial Health

Current Ratio

17.71

FULC Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-1.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0M	3.0M	2.6M	2.8M
2022	17.0M	14.5M	10.7M	6.3M
2021	12.9M	15.2M	18.3M	19.2M
2020	0	0	0	8.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fulcrum Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	tourangeau greg	sold	-57,218	11.7155	-4,884	vice president, finance
Mar 04, 2024	sapir alex	bought	492,028	11.3475	43,360	see remarks
May 10, 2023	tourangeau greg	sold	-695	3.31	-210	principal accounting officer
Jan 20, 2023	ra capital management, l.p.	bought	25,000,000	13.00	1,923,080	-
Jan 13, 2023	gould robert j	sold	-101,490	15.00	-6,766	interim president & ceo
Jan 04, 2023	ra capital management, l.p.	bought	1,314,810	7.27606	180,703	-
Dec 27, 2022	ra capital management, l.p.	bought	24,509	5.9941	4,089	-
Dec 19, 2022	ra capital management, l.p.	bought	582,814	5.8997	98,787	-
Dec 16, 2022	ra capital management, l.p.	bought	7,269,830	5.4195	1,341,420	-
Dec 15, 2022	ra capital management, l.p.	bought	1,302,470	5.495	237,029	-

Which funds bought or sold FULC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BFSG, LLC	new	-	11,423	11,423	-%
Apr 19, 2024	DENALI ADVISORS LLC	reduced	-53.11	-134,326	255,824	0.07%
Apr 16, 2024	COUNTRY TRUST BANK	unchanged	-	81,200	284,956	0.01%
Apr 05, 2024	GAMMA Investing LLC	new	-	425	425	-%
Apr 04, 2024	Mass General Brigham, Inc	new	-	1,938,560	1,938,560	3.39%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-4.66	5,274,110	17,009,900	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	572	10,614,300	11,765,300	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	37,000	108,000	-%
Feb 15, 2024	BARCLAYS PLC	new	-	460,000	460,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	800	2,170,290	2,341,240	-%

Are Funds Buying or Selling FULC?

Are funds buying FULC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FULC

No. of Funds

Unveiling Fulcrum Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	third rock ventures iii, l.p.	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	8.8%	5,469,956	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	18.8%	11,609,704	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	8.9%	5,518,881	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	2.44%	1,506,422	SC 13G/A
Jul 07, 2023	blackrock inc.	2.5%	1,514,425	SC 13G/A
Mar 06, 2023	adage capital partners gp, l.l.c.	5.63%	3,470,547	SC 13G
Feb 14, 2023	third rock ventures iii, l.p.	3.8%	1,962,202	SC 13G/A
Feb 14, 2023	rtw investments, lp	9.6%	4,993,279	SC 13G/A

Recent SEC filings of Fulcrum Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Mar 20, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 08, 2024	144	Notice of Insider Sale Intent
Mar 08, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 27, 2024	S-3	S-3
Feb 27, 2024	10-K	Annual Report

Peers (Alternatives to Fulcrum Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Fulcrum Therapeutics Inc News

Latest updates

Fulcrum Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	14.8%	871	759	880	295	685	1,183	1,882	2,592	5,058	4,935	4,381	4,789	4,225	1,848	2,000	750
Operating Expenses	2.4%	28,863	28,199	28,172	28,235	28,658	25,538	36,117	28,590	28,617	25,705	24,063	21,832	22,012	20,952	17,924	19,546
S&GA Expenses	-1.0%	9,864	9,961	10,323	11,520	10,130	9,707	11,098	10,759	9,705	8,628	6,685	5,498	5,867	5,312	5,149	5,064
R&D Expenses	4.2%	18,999	18,238	17,849	16,715	18,566	15,366	25,019	17,831	18,912	17,077	17,378	16,334	16,145	15,640	12,775	14,482
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	2.00	-	1.00
Net Income	-3.1%	-24,756	-24,017	-23,783	-24,779	-26,135	-23,738	-34,070	-25,928	-23,484	-20,716	-19,648	-16,999	-17,720	-18,962	-15,685	-18,452
Net Income Margin	7.9%	-34.70*	-37.69*	-32.35*	-26.88*	-17.32*	-10.01*	-7.20*	-5.29*	-4.22*	-4.10*	-4.81*	-5.39*	-	-	-	-
Free Cashflow	-1.1%	-23,235	-22,971	-20,980	-24,287	-19,812	-28,165	-28,684	-22,352	-22,377	-22,940	-18,386	-16,488	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-7.6%	258	279	300	321	227	248	195	220	235	256	138	156	130	142	145	95.00	110	116	65.00	86.00
Current Assets	-7.7%	242	262	283	303	208	228	174	200	226	246	129	147	120	132	135	84.00	100	105	51.00	74.00
Cash Equivalents	-15.0%	26.00	30.00	34.00	35.00	35.00	91.00	40.00	33.00	35.00	65.00	57.00	101	57.00	85.00	76.00	25.00	97.00	102	50.00	73.00
Net PPE	-7.6%	5.00	6.00	6.00	7.00	7.00	7.00	8.00	8.00	7.00	8.00	8.00	8.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00	11.00
Liabilities	-3.9%	23.00	23.00	25.00	25.00	28.00	26.00	34.00	31.00	23.00	25.00	27.00	29.00	34.00	37.00	23.00	24.00	23.00	14.00	12.00	10.00
Current Liabilities	-2.8%	14.00	14.00	15.00	14.00	17.00	15.00	22.00	18.00	19.00	21.00	23.00	23.00	27.00	26.00	14.00	14.00	12.00	9.00	6.00	4.00
Shareholder's Equity	-7.9%	235	255	275	296	199	221	161	189	212	231	111	128	95.00	105	122	71.00	87.00	102	-	-
Retained Earnings	-5.1%	-509	-484	-460	-437	-412	-386	-362	-328	-302	-279	-258	-238	-221	-203	-184	-169	-150	-134	-118	-68.12
Additional Paid-In Capital	0.5%	745	741	737	734	612	608	524	519	514	510	369	366	317	309	307	240	238	237	6.00	4.00
Shares Outstanding	18.8%	62.00	52.00	52.00	62.00	52.00	52.00	41.00	41.00	41.00	41.00	33.00	32.00	-	-	-	-	-	-	-	-
Float	-	-	-	163,560	-	-	-	136,819	-	-	-	249	-	-	-	240	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-1.1%	-23,158	-22,906	-20,785	-24,116	-19,696	-27,882	-27,366	-22,106	-21,858	-22,573	-17,821	-16,226	-19,826	-4,504	-14,121	-15,204	-4,495	-13,017	-12,074	-9,897	-
Share Based Compensation	-7.7%	3,449	3,737	3,363	4,253	3,271	3,353	2,879	3,847	3,793	2,658	2,546	2,073	1,677	1,776	2,204	1,693	1,274	1,179	950	821	-
Cashflow From Investing	-3.5%	18,354	19,020	19,875	-93,941	-36,362	-2,279	31,395	19,659	-9,094	-106,636	-26,354	12,415	-14,598	14,090	-226	-56,404	-108	-214	-221	-401	-
Cashflow From Financing	-	287	-	142	117,693	218	80,946	2,811	348	891	137,903	209	47,504	6,255	-83.00	64,686	274	-281	65,200	-529	-47.00	-

FULC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 2,805	$ 6,342
Operating expenses:
Research and development	71,801	76,782
General and administrative	41,668	41,694
Restructuring expenses	0	427
Total operating expenses	113,469	118,903
Loss from operations	(110,664)	(112,561)
Other income, net	13,329	2,690
Net loss	$ (97,335)	$ (109,871)
Earnings Per Share, Basic	$ (1.59)	$ (2.44)
Earnings Per Share, Diluted	$ (1.59)	$ (2.44)
Weighted Average Number of Shares Outstanding, Diluted	61,310	44,991
Weighted Average Number of Shares Outstanding, Basic	61,310	44,991
Comprehensive loss:
Net loss	$ (97,335)	$ (109,871)
Other comprehensive loss:
Unrealized loss on marketable securities	661	(400)
Total other comprehensive loss	661	(400)
Comprehensive loss	$ (96,674)	$ (110,271)

FULC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,563	$ 35,098
Marketable securities	210,658	167,823
Unbilled accounts receivable	537	229
Prepaid expenses and other current assets	5,441	4,369
Total current assets	242,199	207,519
Property and equipment, net	5,216	6,906
Operating lease right-of-use assets	7,176	9,063
Restricted cash	1,092	1,092
Other assets	2,011	2,105
Total assets	257,694	226,685
Current liabilities:
Accounts payable	2,757	3,638
Accrued expenses and other current liabilities	8,726	9,551
Deferred revenue, current portion	0	934
Operating lease liability, current	2,192	2,602
Total current liabilities	13,675	16,725
Operating lease liability, excluding current portion	8,629	10,821
Other liabilities, excluding current portion	197	197
Total liabilities	22,501	27,743
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 61,915,367 and 52,099,211 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	62	52
Additional paid-in capital	744,940	612,025
Accumulated other comprehensive loss	(136)	(797)
Accumulated deficit	(509,673)	(412,338)
Total stockholders’ equity	235,193	198,942
Total liabilities and stockholders’ equity	$ 257,694	$ 226,685

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Alexander C. Sapir
WEBSITE	fulcrumtx.com
INDUSTRY	Biotechnology
EMPLOYEES	89

Fulcrum Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fulcrum Therapeutics Inc? What does FULC stand for in stocks?

FULC is the stock ticker symbol of Fulcrum Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulcrum Therapeutics Inc (FULC)?

As of Tue Apr 23 2024, market cap of Fulcrum Therapeutics Inc is 460.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FULC stock?

You can check FULC's fair value in chart for subscribers.

What is the fair value of FULC stock?

You can check FULC's fair value in chart for subscribers. The fair value of Fulcrum Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fulcrum Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FULC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fulcrum Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FULC is over valued or under valued. Whether Fulcrum Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fulcrum Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FULC.

What is Fulcrum Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, FULC's PE ratio (Price to Earnings) is -4.73 and Price to Sales (PS) ratio is 164.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FULC PE ratio will change depending on the future growth rate expectations of investors.